Cell and gene therapies are considered key elements of modern medicine. They offer new treatment options for severe and previously incurable diseases such as cancer or autoimmune disorders. By individually utilizing customized cells, diseases are expected not only to be alleviated but even permanently cured in the future. A central component of the interdisciplinary collaborative project is the use of Artificial Intelligence (AI) to create digital twins of complex dynamic systems to optimize manufacturing processes, enhance quality, and bring new therapeutic approaches to patients more quickly.

Under the leadership of the internationally renowned company Miltenyi Biotec B.V. & Co. KG, the consortium is developing a new generation of devices that integrate standardized clinical manufacturing processes, automated analytics, AI-supported process monitoring, and the highest product quality. Other project partners include RoweMed AG, University Medicine Rostock, and the Institute for Visual and Analytic Computing at the University of Rostock. In the participating research groups "Hybrid Methods for Artificial Intelligence and Machine Learning" (HAIML, headed by Professor Thomas Kirste) and "Intelligent Data Analytics" (IDA, headed by Professor Martin Becker) at the Institute for Visual and Analytic Computing, scientists from Rostock combine their expertise in capturing complex dynamic processes, analyzing biomedical data, and utilizing deep learning and large language models. The goal is to effectively monitor production processes in bioreactors, efficiently process the resulting data volumes, and generate transparent documentation.

• Miltenyi B.V. & Co.KG, Teterow
• Universitätsmedizin Rostock (UMR), Klinik für Hämatologie, Onkologie und Palliativmedizin am Zentrum für Innere Medizin (ZIM III)
• RoweMed AG - Medical 4 Life, Parchim